Though lower price cards can help ease the burden of higher drug expenses in the short-term, they do not handle the systemic challenges driving up prescription selling prices while in the U.S. Broader plan adjustments could deal with the foundation results in of mounting drug costs, such as deficiency of transparency in pricing along with the posit